Boehringer Ingelheim reports phase 3 SYNCHRONIZE-2 positive results for Survodutide in obesity with type 2 diabetes

Boehringer Ingelheim / Zealand Pharma/Survodutide (BI 456906)

Boehringer Ingelheim reported positive SYNCHRONIZE-2 results for Survodutide in patients with obesity and type 2 diabetes. Participants achieved 13.1% weight loss versus 3.1% placebo after 76 weeks. Co-primary endpoints met; HbA1c reduced by 1.21%, waist circumference by 11.1 cm.

• 13.1% weight loss on Survodutide vs 3.1% placebo after 76 weeks.
• HbA1c reduction of 1.21% from baseline 7.4%, showing glycemic control improvement.
• Waist circumference reduced 11.1 cm versus 3.5 cm on placebo.
• Results presented at the 62nd European Association for the Study of Diabetes Annual Meeting (October 1, 2026) and published in The New England Journal of Medicine.